A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer

Published on Jul 1, 2019in Annals of Oncology18.274
· DOI :10.1093/ANNONC/MDZ157.004
Zev A. Wainberg10
Estimated H-index: 10
(Ronald Reagan UCLA Medical Center),
Patrick McKay Boland15
Estimated H-index: 15
(Roswell Park Cancer Institute)
+ 8 AuthorsAndrew Dean12
Estimated H-index: 12
(St John of God Subiaco Hospital)
Cited By3
#1Francesca Simionato (University of Verona)H-Index: 14
#2Camilla Zecchetto (University of Verona)H-Index: 7
Last. Davide Melisi (University of Verona)H-Index: 31
view all 34 authors...
Background Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance ...
2 CitationsSource
#1Arnav Mehta (Broad Institute)H-Index: 14
#2William L. Hwang (Broad Institute)H-Index: 20
Last. Colin D. WeekesH-Index: 27
view all 3 authors...
Metastatic pancreatic adenocarcinoma remains one of the deadliest cancer diagnoses with 5-year survival rates as low as 3%. For decades, gemcitabine remained the mainstay of systemic therapy before the approvals of FOLFIRINOX and gemcitabine with nab-paclitaxel. Despite these advances in the early 2010s, almost all patients progress on systemic chemotherapy and significant effort is needed to identify novel therapeutic targets. A promising array of approaches is currently under investigation, en...
#1Ritu R. Singh (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 3
#2Eileen M. O'Reilly (Cornell University)H-Index: 73
Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced stage, with systemic therapy being the mainstay of treatment. Survival continues to be limited, typically less than 1 year. The PDAC microenvironment is characterized by a paucity of malignant epithelial cells, abundant stroma with predominantly immunosuppressive T cells and myelosuppressive-type macrophages (M2), and hypovascularity. The current treatment options for metastatic PDAC are modified (m)FOLFIRINOX /FOLFIRI...
19 CitationsSource